Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture
(NASDAQ: SGMO) $3.20 + 0.50 (18.519%) High
3.35
Low
2.70
Volume 1,601,307 4:00 PM ET on Dec 9, 2016 Delayed at least 20 minutes

Investor Presentation